🔴 Neurosense Therapeutics is trading 14% down today following 1-for-20 reverse stock split

Neurosense Therapeutics is trading 14.01% down now at $6.04 after heightened volatility following its 1-for-20 reverse stock split, effective September 14, 2026.

• The split reduced outstanding shares from approximately 37.9 million to 1.9 million.
• Nasdaq confirmed the corporate action.
• Broader biotech weakness is adding pressure, with XBI down 2.11% during the September 16 session.